| CAS NO: | 87269-97-4 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 87269-97-4 |
| 别名 | 雷米普利,Ramipril Diacid |
| 化学名 | (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]octahydro-cyclopenta[b]pyrrole-2-carboxylic acid |
| Canonical SMILES | O=C([C@H](C)N[C@H](C(O)=O)CCC1=CC=CC=C1)N2[C@]3([H])[C@](CCC3)([H])C[C@H]2C(O)=O |
| 分子式 | C21H28N2O5 |
| 分子量 | 388.5 |
| 溶解度 | ≤1mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | pKi= 9.08 in human heart Ramiprilat is an angiotensin-converting enzyme (ACE) inhibitor. ACE inhibitors help relax blood vessels and prevent an enzyme from producing angiotensin II, a substance narrowing blood vessels and releasing hormones that can raise blood pressure. In vitro: Pretreatment with ramiprilat could significantly attenuate the recovery of B2 kinin receptors in while increasing that from membranes lacking caveolin, and such effect was not because of the inhibition of bradykinin degradation. Ramiprilat could also decrease [3H]bradykinin binding to CR membranes. In addition, ramiprilat treatment led to reactivation of the B2 receptor in bradykinin-stimulated cells [1]. In vivo: In previous animal study, when compared with the control rats, diabetic rats showed decreased creatinine clearance rate, increased urinary protein excretion and blood pressure, as well as development of tubulointerstitial fibrosis, glomerulosclerosis, and inflammatory cell infiltration. Furthermore, the blocking angiotensin II with ramipril (the prodrug of ramiprilat) was able to significantly improve all of these parameters [2]. Clinical trial: Previous study showed that ramipril at 10 mg/day could significantly reduce the incidence of MI, stroke or death from cardiovascular causes in patients who were at increased risk for the development of ischaemic cardiovascular events [3]. References: |
m.cnreagent.com